Welcome to ActivSignal
ActivSignal is a molecular diagnostic company focused on developing early detection assays for cancer.
Our mission is to improve cancer outcomes by detecting cancer earlier, when it can still be treated.
Company
At ActivSignal, we are focused on developing better assays for early cancer detection. Our technology for profiling proteins and other non-DNA biomarkers identifies multi-target bio-signatures in patient samples, offering a highly specific and sensitive platform for early cancer detection. Our team is comprised of experienced scientists dedicated to advancing cancer diagnostics and improving patient outcomes.
Technology
Multiplex Biomarker Quantification
ActivSignal’s MPAD platform technology is a highly specific and sensitive platform for profiling proteins and other non-DNA biomarkers in multiplex.
Multiplex Paired-Antibody Amplified Detection (MPAD) technology detects a target molecule using a carefully selected pair of antibodies, thus boosting specificity. Hundreds of biomarkers can be measured in multiplex from the same small sample with high specificity and sensitivity.
Approach
Earlier Cancer Detection
The MPAD read-out from the patient sample, across the multiple proteins and other biomarkers in the Panel, is used to create a “bio-signature” for that individual.
AI is then harnessed to match this bio-signature against the subtle signatures of even early-stage cancer and other related conditions, in order to produce a diagnosis.
The combination of high specificity and sensitivity, applied to biologically important biomarkers, even those in lower abundance, and in multiplex, enables the detection of cancer at an earlier stage.
Recognition
ActivSignal's work has been supported by multiple grant awards from the National Science Foundation and the MassVentures START program.
